Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | YAP1 | P46937 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407452 | 0.93 | MTNR1B (0.52) | MTNR1BSLC6A5MTNR1AYAP1GPR119 | |
| SCHEMBL6409482 | 0.90 | MTNR1B (0.52) | MTNR1BMTNR1AYAP1GPR119 | |
| SCHEMBL6409504 | 0.87 | MTNR1B (0.49) | MTNR1BMAPTMTNR1AGPR119 | |
| SCHEMBL6409507 | 0.86 | SLC6A5 (0.48) | MTNR1BSLC6A5MAOAMAOB | |
| SCHEMBL6403250 | 0.86 | MTNR1B (0.48) | MTNR1BMAPTMTNR1AGPR119 | |
| SCHEMBL6405980 | 0.86 | MTNR1B (0.48) | MTNR1BSLC6A5MTNR1AYAP1GPR119 | |
| SCHEMBL6408595 | 0.82 | MTNR1B (0.56) | MTNR1BMTNR1AGPR119 | |
| SCHEMBL22411105 | 0.82 | MAOA (0.47) | MTNR1BSLC6A5MAOAMAOB | |
| SCHEMBL6422049 | 0.81 | MTNR1B (0.73) | MTNR1BMTNR1A | |
| SCHEMBL6409459 | 0.81 | MTNR1B (0.54) | MTNR1BMTNR1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | MTNR1B 63/4885MAPT 3268/4885SLC6A5 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.